BiotechTube

REOLYSIN + Carboplatin + Paclitaxel

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Melanoma

Conditions

Metastatic Melanoma

Trial Timeline

Sep 1, 2009 → Oct 1, 2014

NCT ID
NCT00984464

About REOLYSIN + Carboplatin + Paclitaxel

REOLYSIN + Carboplatin + Paclitaxel is a phase 2 stage product being developed by Oncolytics Biotech for Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00984464. Target conditions include Metastatic Melanoma.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Melanoma were approved

Approved (20) Terminated (8) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enfortumab VedotinAstellas PharmaApproved
✅EligardAstellas PharmaApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00984464Phase 2Completed

Competing Products

20 competing products in Metastatic Melanoma

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
AbemaciclibEli LillyPre-clinical
26
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
SYNB1891 + AtezolizumabSynlogicPhase 1
11
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
40
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
32
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Induction therapyChugai PharmaceuticalPhase 2
42
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
35
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
35
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
GC33Chugai PharmaceuticalPhase 1
29
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44